Burning Rock Biotech (BNR) Net Cash Flow (2019 - 2026)

Burning Rock Biotech (BNR) has reported Net Cash Flow for 8 consecutive years, with -$4.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 24.25% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at -$8.4 million (up 70.81% YoY), while the FY2025 annual figure was -$4.4 million, up 66.62% from the prior year.
• Net Cash Flow came in at -$4.3 million for Q1 2026 at Burning Rock Biotech, down from $3.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $3.2 million in Q4 2025, with the low at -$25.4 million in Q1 2022.
• Average Net Cash Flow over 5 years is -$10.6 million, with a median of -$11.5 million recorded in 2023.
• Across the five-year window, Net Cash Flow sank 197.37% in 2022 and soared 196.85% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$22.8 million in 2022, then soared by 88.7% to -$2.6 million in 2023, then jumped by 196.85% to $2.5 million in 2024, then rose by 29.84% to $3.2 million in 2025, then sank by 232.48% to -$4.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$4.3 million, $3.2 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.